Furthermore, concomitant chemotherapy with trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) antibody, has been reported to substantially improve outcomes in resected HER2-positive breast cancer (Mackey et al, 2009). The gene discussed is ERBB2; the disease is breast cancer.